MEPs Against Cancer
feb 2 2013.jpg
mac group picture.jpg
IMPROVING DIAGNOSIS OF RARE CANCERS IN EUROPE
Expert Workshop 10-11 February 2014, Brussels
Lugano, Switzerland. 6 February 2014. Inappropriate or late diagnosis is a major hurdle for the proper treatment of patients with rare cancers. In order to discuss solutions to improve the pathologic diagnosis of patients fighting these diseases, RARE CANCERS EUROPE, together with the European Society for Medical Oncology (ESMO) and the European Society of Pathology (ESP) organised a workshop in Brussels, Belgium, on 10 and 11 February 2014.
During the workshop, a Consensus Statement on Improving the Pathologic Diagnosis of Rare Cancers was drafted by a panel of expert Pathologists and Oncologists, specializing in rare cancers. The implementation of the recommendations contained in this position statement will be crucial to improve the lives of rare cancer sufferers.
For conclusions and other information and interview opportunities, please contact Jackie Partarrieu at ESMO on:
THe MEPs Against Cancer Interest Group is open to all MEPS
Current MAC MEPs include: Alojz Peterle (MAC President), Michele Rivasi, Nessa Childers, Pavel Poc, Dagmar Roth-Behrendt, Minodora Cliveti, Linda McAven and Glenis Willmott among others
... current and candidate MEPS can help us to support cancer control in the EU by signing up to MAC by sending an email to the secretariat ....
The MEPs Against Cancer work together in order to improve cancer prevention and control in Europe in the belief that European cooperation adds value to member state actions. In order to address the challenges faced by the EU, MAC will work together with the European Council, the Commission, other institutions and relevant organisations to reduce cancer incidence by 15% by the year 2020. For a fuller situational analysis of the challenges and opportunities in cancer control in the EU, please click here for MAC Election Manifesto Background Paper
In the 2014 to 2019 legislature the strategic goal of the MEPs Against Cancer Group will be:
To reduce cancer incidence by promoting prevention, reduce mortality by ensuring equitable access to high quality treatment and care, and ensure a good quality of life for cancer patients and survivors.
Key areas of MAC engagement 2014 to 2019 will include (but not be limited to):
EQUALITY: Address factors such as the impact of austerity measures on healthcare services, the unequal impact of cancer on poorer individuals and households across the EU, access to medicines and the cost of medicines and treatments.
PREVENTION: strengthen cancer prevention policies in
RESEARCH: Encourage more investment in all scientific forms of cancer research and explore ways of encouraging innovation in research.
REGISTRATION: Support the extension and improvement of population based registries in all member states. National Cancer Control Plans should be based on cancer registries data.
PROTECTION: Protect the data of individuals that are given and used for health research.
PATIENTS: Ensure meaningful inclusion of the patient voice within every cancer action.
QUALITY: Reinforce initiatives to improve quality of cancer care, eg the creation of European reference centres for cancer treatments.
RARE CANCERS: Ensure political attention to rare cancers within the framework of the priorities of the Rare Cancer Europe network.
Current and Candidate MEPs who sign the manifesto will be sent the MAC logo by the MAC secretariat for use in election campaign material and will be contact by the MAC secretariat to discuss future collaboration.